ASRT vs. ORMP, BYSI, GNLX, CLSD, ANIX, IOBT, ALLK, ETON, CNTB, and QTTB
Should you be buying Assertio stock or one of its competitors? The main competitors of Assertio include Oramed Pharmaceuticals (ORMP), BeyondSpring (BYSI), Genelux (GNLX), Clearside Biomedical (CLSD), Anixa Biosciences (ANIX), IO Biotech (IOBT), Allakos (ALLK), Eton Pharmaceuticals (ETON), Connect Biopharma (CNTB), and Q32 Bio (QTTB). These companies are all part of the "pharmaceutical preparations" industry.
Oramed Pharmaceuticals (NASDAQ:ORMP) and Assertio (NASDAQ:ASRT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, community ranking, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.
12.7% of Oramed Pharmaceuticals shares are held by institutional investors. Comparatively, 49.0% of Assertio shares are held by institutional investors. 12.0% of Oramed Pharmaceuticals shares are held by insiders. Comparatively, 3.2% of Assertio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Assertio has a consensus target price of $5.50, indicating a potential upside of 414.02%. Given Oramed Pharmaceuticals' higher probable upside, analysts clearly believe Assertio is more favorable than Oramed Pharmaceuticals.
Oramed Pharmaceuticals received 211 more outperform votes than Assertio when rated by MarketBeat users. Likewise, 74.82% of users gave Oramed Pharmaceuticals an outperform vote while only 58.76% of users gave Assertio an outperform vote.
Oramed Pharmaceuticals has higher earnings, but lower revenue than Assertio. Assertio is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Oramed Pharmaceuticals has a net margin of 0.00% compared to Oramed Pharmaceuticals' net margin of -234.40%. Oramed Pharmaceuticals' return on equity of 10.80% beat Assertio's return on equity.
In the previous week, Assertio had 8 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 9 mentions for Assertio and 1 mentions for Oramed Pharmaceuticals. Oramed Pharmaceuticals' average media sentiment score of 0.21 beat Assertio's score of -0.06 indicating that Assertio is being referred to more favorably in the news media.
Oramed Pharmaceuticals has a beta of 1.87, suggesting that its share price is 87% more volatile than the S&P 500. Comparatively, Assertio has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.
Summary
Oramed Pharmaceuticals beats Assertio on 9 of the 17 factors compared between the two stocks.
Get Assertio News Delivered to You Automatically
Sign up to receive the latest news and ratings for ASRT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ASRT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Assertio Competitors List
Related Companies and Tools
